News und Analysen

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca^® (rucaparib) in multiple tumor types have

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2020, equal to revenue reported for the second quarter of 2019 and down 1.7% on a

Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief

Veeva Systems (NYSE: VEEV) today announced that Barry Greene, president at Alnylam Pharmaceuticals, and Andy Schmeltz, global president and general manager of oncology at Pfizer Inc., will be

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of

Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on July 22, 2020, to all shareholders of record as of the close of

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders¹ that showed

Leading health and well-being company Humana Inc. (NYSE: HUM) and Healthmap Solutions, Inc., a specialty population health management company with kidney health expertise, today announced a

The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling

Paris and Boston, May 19^th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced a new program to invest in domestic and geographically diverse manufacturers to ensure a robust and resilient

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval^® Sutureless Implant Versus Standard-Aortic Valve Replacement

Veeva Systems (NYSE:VEEV) today announced a new partner program to help CROs build studies faster using Veeva Vault EDC. As part of the CRO partner program, CROs are trained and receive best

Veeva Systems (NYSE: VEEV) today announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials. Vault Site Connect automates the flow of

Veeva Systems (NYSE: VEEV) today announced MyVeeva, a new application for clinical research sites. With capabilities for virtual visits, patient adherence, ePRO, eConsent, eSource and an easy to

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx^® (cabozantinib) versus Stivarga^® (regorafenib) for

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:

$750,000,000 aggregate principal amount of 0.800% notes due 2025
$1,000,000,000

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.

Clovis Oncology intends to offer, subject to market and other